Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles

  • Gonzalo-Calvo, David de
  • Thum, Thomas
We have read the comment by Schmitz and Brand with great interest. We believe that several questions should be answered before accepting non-coding RNAs (ncRNAs) as functional markers in the context of exercise. Contrary to what happens with other cardiovascular therapies,1 the potential of ncRNAs to predict the response to acute exercise and/or training programs remains to be addressed. Previous studies demonstrated that circulating microRNAs (miRNAs) correlate with aerobic performance parameters such as VO2max.2 Specific circulating miRNA profiles have been observed in individuals with different cardiorespiratory fitness levels.3 Therefore, circulating ncRNAs could be useful to monitor cardiovascular health. Nonetheless, whether the baseline ncRNA signature reflects the molecular configuration required for any exercise protocol to exert a preventive and/or therapeutic effect in healthy subjects or cardiovascular patients is unknown. Furthermore, the results in the field of circulating miRNAs and exercise are heterogeneous and hardly comparable due to differences in the experimental designs, characteristics of the participants, and technical approaches.4 Additionally, the translation of ncRNAs to clinical practice is controversial due to relevant methodological limitations.1 This situation might not be linked to the poor performance of ncRNAs as biomarkers but additional efforts are needed, especially in terms of reproducibility., Juan de la Cierva-Incorporacio´n grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393 to D.d.G.-C.); CIBER Cardiovascular (CB16/11/00403 to D.d.G.-C.) is a project of the Instituto de Salud Carlos III; The EU, project HOMAGE, the ERANET-CVD LIPCAR-HF and the DFG (KFO311) to T.T, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

  • de Boer, Rudolf A..
  • Hulot, Jean-Sébastien
  • Tocchetti, Carlo Gabriele|||0000-0001-5983-688X
  • Aboumsallem, Joseph Pierre
  • Ameri, Pietro|||0000-0001-7167-7287
  • Anker, Stefan|||0000-0002-0805-8683
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Bertero, Edoardo
  • Coats, Andrew J. S.
  • Čelutkienė, Jelena
  • Chioncel, O.|||0000-0002-3197-3628
  • Dodion, Pierre
  • Eschenhagen, Thomas
  • Farmakis, Dimitrios|||0000-0001-8364-3447
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Jäger, Dirk
  • Jankowska, Ewa A.
  • Kitsis, Richard N.
  • Konety, Suma H.
  • Larkin, James
  • Lehmann, Lorenz
  • Lenihan, Daniel J.
  • Maack, Christoph
  • Moslehi, Javid J.
  • Müller, Oliver J.
  • Nowak-Sliwinska, Patrycja
  • Piepoli, Massimo Francesco
  • Ponikowski, Piotr|||0000-0002-3391-7064
  • Pudil, Radek
  • Rainer, Peter P.|||0000-0002-2840-6454
  • Ruschitzka, Frank
  • Sawyer, Douglas
  • Seferovic, Petar M.
  • Suter, Thomas
  • Thum, Thomas|||0000-0003-4360-1511
  • van der Meer, Peter|||0000-0002-9705-4413
  • Van Laake, Linda W.
  • von Haehling, Stephan
  • Heymans, Stephane
  • Lyon, Alexander R.
  • Backs, Johannes|||0000-0002-2322-2699
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre-clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time. We describe the co-occurrence of cancer and heart failure (HF), their potential shared risk factors, and their pathophysiological mechanisms. We advocate intense interaction between cardiologists and oncologists to achieve unifying hypotheses and collaborative pre-clinical and clinical studies.